ReviewAdvances in experimental medicine and biology2026
Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant Cyclophosphamide.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posttransplant cyclophosphamide (PTCy) represents a paradigm shift in the prevention of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). As a high-dose, posttransplant immunomodulatory agent, PTCy offers a unique mechanism to facilitate graft tolerance, mitigate GVHD, and preserve graft-versus-leukemia (GVL) effects. The beneficial effects of PTCy on GVHD appears to be independent of donor type, graft source, or conditioning regimen intensity. This chapter provides an in-depth analysis of the mechanisms underlying PTCy and its clinical applications in haploidentical, HLA-matched, and -mismatched HSCT, highlighting its transformative impact in transplantation medicine. PTCy is emerging as a new standard GVHD prophylaxis for all HSCT settings.
Indexed as
Identifiers
40579688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.